[isoalloxazine binds to and results in decreased activity of ADORA2B protein] which results in decreased susceptibility to alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; more ...
ADORA2B mutant form inhibits the reaction [1,7-dimethylxanthine results in decreased expression of and results in decreased activity of HSD11B2 protein]; more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADORA2B mRNA
[isoalloxazine binds to and results in decreased activity of ADORA2B protein] which results in decreased susceptibility to alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADORA2B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADORA2B mRNA
[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADORA2B mRNA; more ...
[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADORA2B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ADORA2B mRNA
[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADORA2B mRNA; more ...
[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADORA2B mRNA
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
supported in part by the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University, and the Genome Information Upgrading Program of the National BioResource Project, Japan Agency for Medical Research and Development
Gene-Chemical Interaction Annotations
